Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

FDA a pproves Dupixent ® (dupilumab) as f irst t reatment for adult s and children aged 12 and older with e osinophilic e sophagitis

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

TARRYTOWN, N.Y. and PARIS , May 20, 2022 /PRNewswire/ -- Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this complex disease Eosinophilic esophagitis is a chronic, progressive inflammatory disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly Approval represents first indication for Dupixent in a gastrointestinal disease and fourth disease indicated overall Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

Checkmate Pharmaceuticals

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Checkmate will receive only $10.50 in cash for each share of Checkmate that they own. KSF is seeking to determine whether this consideration and the

CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

ROCHESTER, Minn. , May 17, 2022 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr.

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

Cigna

Ingredion

MetLife

Micron Technology

Weis Markets

Certain predators can't see their prey if the prey holds still.

My 'Do Nothing Club' Returned 68% in the Past Year

Elicio Therapeutics Inc

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, announced today that it has entered into a clinical supply agreement with Regeneron to evaluate the safety and efficacy of Elicio's lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron's Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. The combination therapy will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC). The study, which is expected to begin in 2023, will be conducted by Elicio Therapeutics. Each party will provide their respective agent for the trial. Libtayo is being jointly developed by Regeneron and Sanofi.

Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors

$75,000 Top Award Goes to 17-year-old Robert Sansone for pioneering invention to improve electric motor efficiency in the largest international STEM competition for teens  TARRYTOWN, N.Y. and WASHINGTON, May 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  and Society for Science  (the Society) announced that Robert Sansone, 17, of Fort Pierce, FL, won the $75,000 top award in the 2022 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global high school competition, for a project that explored high-efficiency alternatives to induction motors.

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

The pharmaceutical company's COVID-19 treatment wasn't the only product suffering this past quarter.

Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?

CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Conference Call Participants Chris Raymond - Piper Sandler Cory Kasimov - JP Morgan Evan Siegerman - BMO Capital Markets Salveen Richter - Goldman Sachs Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Capital Luke Hermann - Baird Brittany Woods - Cowen & Co. Dane Leone - Raymond James Charlie Yang - Morgan Stanley Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals first quarter 2022 earnings conference call. My name is Gigi and I'll be your operator for today's call.

Regeneron Pharmaceuticals (REGN) CEO, Leonard Schleifer on Q1 2022 Results - Earnings Call Transcript

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate.  Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV.

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates

The pharmaceutical company posts first-quarter revenue of $2.97 billion, up 17% from a year earlier.

Regeneron Stock Rises as First-Quarter Earnings Top Forecasts

(Reuters) -Regeneron Pharmaceuticals reported a 13% fall in quarterly profit on Wednesday, as sales of its COVID-19 antibody cocktail were hit by the U.S. health regulator's decision to limit its use.

Regeneron quarterly profit drops as COVID antibody sales hit

Regeneron Pharmaceuticals Inc. shares REGN, +1.30% rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 million, or $8.61 a share, for the quarter, down from $1.115 billion, or $10.09 a share, in the year-earlier period.

Regeneron shares up 1.4% premarket after earnings top estimates

TARRYTOWN, N.Y. , May 4, 2022 /PRNewswire/ -- First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV ® (a)(b), revenues increased 25% First quarter 2022 EYLEA® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021 First quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021 First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS(a) of $11.49 Dupixent approved in EU for children aged 6–11 years with severe asthma; FDA priority review granted for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022 and provided a business update.

Regeneron Reports First Quarter 2022 Financial and Operating Results

Moderna

Ngm Biopharmaceuticals Inc

Seagen

TG Therapeutics

After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.

5 Graham's Lost Formula Biotech Stocks to Consider for May

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

Biogen

Novo Nordisk

Vertex Pharmaceuticals

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

AbbVie

Merck

The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.

Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?

Amgen

Corcept Therapeutics

Harmony Biosciences Holdings

Incyte

Bio-Techne

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

7 Best Biotech Stocks to Build Your Portfolio

Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.

Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) shares are up 300% after the clinical-stage company focusing on novel tech harnessing the immune system's power in the fight against cancer announced a definitive agreement to be acquired by Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Regeneron will acquire Checkmate's common shares for $10.5 per share for almost $250 million.

News for Regeneron Pharmaceuticals Stock (REGN)